Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
Merck & Co., Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$115.60 |
52 Week High | US$120.00 |
52 Week Low | US$90.70 |
Beta | 0.38 |
1 Month Change | -3.67% |
3 Month Change | 18.81% |
1 Year Change | 17.36% |
3 Year Change | 73.57% |
5 Year Change | 55.56% |
Change since IPO | 283.55% |
Recent News & Updates
Recent updates
Shareholder Returns
6MK | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 3.0% | 2.3% | 1.9% |
1Y | 17.4% | -25.9% | 7.3% |
Return vs Industry: 6MK exceeded the German Pharmaceuticals industry which returned -26.3% over the past year.
Return vs Market: 6MK exceeded the German Market which returned 6.4% over the past year.
Price Volatility
6MK volatility | |
---|---|
6MK Average Weekly Movement | 2.6% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6MK has not had significant price volatility in the past 3 months.
Volatility Over Time: 6MK's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1891 | 71,000 | Rob Davis | https://www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
6MK fundamental statistics | |
---|---|
Market cap | €293.02b |
Earnings (TTM) | €337.00m |
Revenue (TTM) | €55.50b |
871.0x
P/E Ratio5.3x
P/S RatioIs 6MK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6MK income statement (TTM) | |
---|---|
Revenue | US$60.12b |
Cost of Revenue | US$15.92b |
Gross Profit | US$44.20b |
Other Expenses | US$43.84b |
Earnings | US$365.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 0.14 |
Gross Margin | 73.53% |
Net Profit Margin | 0.61% |
Debt/Equity Ratio | 93.1% |
How did 6MK perform over the long term?
See historical performance and comparison